A RISK-BENEFIT ASSESSMENT OF ZIDOVUDINE IN THE PREVENTION OF PERINATAL HIV TRANSMISSION

被引：20

作者：

NEWELL, ML

GIBB, DM

机构：

[1] Unit of Epidemiology and Biostatistics, Institute of Child Health, London, WC1N 1EH

来源：

DRUG SAFETY | 1995年 / 12卷 / 04期

关键词：

D O I：

10.2165/00002018-199512040-00007

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Mother-to-child transmission is the main mode of acquisition of HIV infection for children, and the estimated rate of vertical transmission ranges from 15 to 20% in Europe, 15 to 25% in the US and 25 to 35% in Africa. Vertical transmission is associated with clinical and immunological progression of disease in the mother, breastfeeding and possibly with vaginal delivery. Recently, the findings of the American/French AIDS Clinical Trial Group (ACTG) trial 076 showed that in women with mildly symptomatic HIV disease and no prior treatment with antiretroviral drugs during the pregnancy, zidovudine (ZDV, 3'-azido-3'-droxy-thymidine, AZT) reduced the risk of vertical transmission when administered during pregnancy and delivery and to the infant in the first 6 weeks of life. No significant adverse effects were observed in either the mothers or neonates. Although the results of the American/French trial on the use of zidovudine to prevent vertical transmission are encouraging, many questions remain unanswered. The optimal timing of administration of zidovudine is unknown, as is its effectiveness in women with clinical characteristics that differ from those of the women in the trial. Concern has been expressed about the possibility of long term effects of exposure of zidovudine during pregnancy, both for the mother and the infant (of whom 4 out of 5 are uninfected anyway) and the implications for antenatal screening. Further trials with different zidovudine regimens and other strategies to prevent vertical transmission are being planned in several countries.

引用

页码：274 / 282

页数：9

共 43 条

[21]

Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection, Lancet, 343, (1994)

[22]

Fischl M.A., Dickinson G.M., Scott G.B., Et al., Evaluation of heterosexual partners, children and household contacts of adults with AIDS, JAMA, 257, (1987)

[23]

Richman D.D., Fischl M.A., Grieco M.H., The toxicity of azidothymidine [AZT] in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial, N Engl J Med, 317, (1987)

[24]

Boucher F.D., Modlin J.F., Weiler S., Et al., Phase 1 evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus, J Pediatr, 122, (1994)

[25]

Lipschutz S.E., Orav E.J., Sanders S.P., Et al., Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine, N Engl J Med, 327, (1992)

[26]

Hamilton J.D., Hartigan P.M., Simberkoff, Et al., A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection — results of the Veterans Affairs Cooperative Study, N Engl J Med, 326, (1992)

[27]

McKinney R.E., Maha M.A., Connor E.M., Et al., A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease, N Engl J Med, 324, (1991)

[28]

Ayers K.M., Preclinical toxicology of zidovudine: an overview, Am J Med, 85, (1988)

[29]

Watts D.H., Brown Z.A., Tartaglione T., Et al., Pharmacokinetic disposition of zidovudine during pregnancy, J Infect Dis, 163, (1991)

[30]

Ferrazin A., de Maria A., Gotta C., Et al., Zidovudine therapy of HIV-1 infection during pregnancy: assessment of the effect on the newborns, J Acquir Immune Defic Syndr, 6, (1993)

← 1 2 3 4 5 →